Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Novocure is a medical instruments & supplies business based in the US. Novocure shares (NVCR) are listed on the NASDAQ and all prices are listed in US Dollars. Novocure employs 1,167 staff and has a trailing 12-month revenue of around $542.6 million.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $90.90 |
|---|---|
| 52-week range | $56.39 - $120.03 |
| 50-day moving average | $80.87 |
| 200-day moving average | $77.14 |
| Wall St. target price | $104.43 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.57 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $90.9 from 2023-01-27
| 1 week (2023-01-20) | 2.72% |
|---|---|
| 1 month (2022-12-27) | 32.01% |
| 3 months (2022-10-31) | 28.64% |
| 6 months (2022-07-28) | 29.41% |
| 1 year (2022-01-31) | 32.41% |
|---|---|
| 2 years (2021-01-29) | -43.53% |
| 3 years (2020-01-31) | 11.59% |
| 5 years (2018-01-30) | 299.56% |
| Revenue TTM | $542.6 million |
|---|---|
| Gross profit TTM | $420.8 million |
| Return on assets TTM | -3.78% |
| Return on equity TTM | -19.03% |
| Profit margin | -15.05% |
| Book value | $4.24 |
| Market capitalisation | $9.1 billion |
TTM: trailing 12 months
We're not expecting Novocure to pay a dividend over the next 12 months.
Over the last 12 months, Novocure's shares have ranged in value from as little as $56.39 up to $120.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novocure's is 0.7656. This would suggest that Novocure's shares are less volatile than average (for this exchange).
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.